Sinocelltech Group (688520) Stock Overview

Sinocelltech Group Limited, a biotech company, engages in the research and development, and industrialization of recombinant proteins, monoclonal antibodies, and vaccines in China. The company offers AnpingxiA (repertuzumab injection), an anti-tumor product; Anjiayin for the treatment of the rare disease hemophilia A; coronavirus 2-valent, a trimer protein vaccine; and mutant strain recombinant protein vaccines SCTV01C and SCTV01E. Its pipeline products include SCT630 used for the treatment of autoimmune diseases; SCT510 for the treatment of solid tumors; SCT-I10A, a monoclonal antibody injection which is in phase 3 trials for the treatment of solid tumors; SCTV01, a new generation vaccine which is in phase 3 trials for the treatment of corona virus; SCT510 for the treatment of solid tumors; SCT200, a monoclonal antibody injection for the treatment of solid tumors; and SCT1000, which is in phase 3 clinical trials for the treatment of human papillomavirus, as well as SCTA01 which is in phase 2/3 clinical research trials for the treatment of SARS COV-2. The company was founded in 2007 and is based in Beijing, China. Sinocelltech Group Limited operates as a subsidiary of Lhasa Alike Investment Consulting Co., Ltd.